<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03022734</url>
  </required_header>
  <id_info>
    <org_study_id>4-2016-0410</org_study_id>
    <nct_id>NCT03022734</nct_id>
  </id_info>
  <brief_title>Short Course Radiotherapy, Unresectable Rectal Cancer, Liver Metastasis</brief_title>
  <official_title>A Phase II Study of Neoadjuvant Systemic Chemotherapy With Short Course Radiotherapy in Patients With Unresectable Rectal Cancer and Liver Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is the increase of resection rate of primary cancer in rectal after
      short course radiotherapy without interrupt chemotherapy schedule during the period of
      chemotherapy. Radiation therapy is followed by additional chemotherapy to prevent the
      progression of systemic metastasis, and to reduce the incidence of rectal carcinoma including
      metastasis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete resection (R0) rate for rectal and liver lesions</measure>
    <time_frame>after surgical resection, an average of 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate (RECIST V1.1)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Rectal Cancer, Metastatic</condition>
  <arm_group>
    <arm_group_label>chemotherapy with radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cetuximab or Bevacizumab, FOLFOX or FOLFIRI, radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <description>cetuximab 250mg/m2 or bevacizumab 5mg/kg, FOLFOX (oxaliplatin 85mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2) or FOLFIRI (irinotecan 180mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2)</description>
    <arm_group_label>chemotherapy with radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>After FOLFOX 4cycle, subject have short course radiotherapy 5Gy for 5 days.</description>
    <arm_group_label>chemotherapy with radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pathologically confirmed for unresectable (impossible to try Total mesorectal
             excision) rectal cancer with liver metastasis

          -  over 19 years

          -  Eastern Cooperative Oncology Group 0-1

          -  Proper organ function

          -  more than one target lesion (standard by Response Evaluation Criteria in Solid Tumors
             1.1)

          -  Who should sign on the Informed consent form before participate the trial.

        Exclusion Criteria:

          -  Metastasis in other organ except liver

          -  Chronic active hepatitis or cirrhosis

          -  History of treatment for metastatic colorectal cancer

          -  Subject pregnant or breast feeding

          -  Uncontrolled disease

          -  Have had adjuvant therapy

          -  Uncontrolled peripheral nerve infection

          -  Alcoholic or drug addict

          -  Subject currently is enrolled in or â‰¤30 days from ending other clinical trial.

          -  History of other type of cancer except resolved from skin cancer and cervical cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sang Joon Shin</last_name>
    <phone>82-2-2228-8130</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Joon Shin</last_name>
      <phone>82-2-2228-8130</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2017</study_first_submitted>
  <study_first_submitted_qc>January 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2017</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Sang Joon Shin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

